Business
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
New data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer SOUTH SAN
About this update from Veracyte, Inc.
[{"type":"text","content":"\nNew data support continued expansion of the company’s tests, including determining treatment prognosis in men with advanced prostate cancer\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris.\n\n“The abstracts we’ll share at ESMO 2022 reinforce the value our genomic tests bring to physicians diagnosing and treating cancer patients,” said Marc Stapley, Veracyte’s chief executive officer. “We are particularly excited about new data from a post-hoc analysis that evaluated the clinical performance of our Decipher Prostate test in one arm of the large, multi-center, randomized STAMPEDE trial. We believe these data may help expand the Decipher test’s availability to advanced prostate cancer patients in the United States, and also support our plans to offer the Decipher Prostate test as an IVD on the nCounter Analysis System for use outside of the United States where laboratories can perform it locally.”\n\nFollowing are details of the abstracts that will be shared as part of the ESMO 2022 Congress:\n\n\n\nTitle:\n\n\n\n\nClinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): an ancillary study of the STAMPEDE AAP trial\n\n\n\n\n\nPresenter:\n\n\n\n\nMarina Perry, PhD, University College London Cancer Institute\n\n\n\n\n\nDate/Time:\n\n\n\n\nSeptember 11, 2022, 8:40-8:50 a.m. CEST\n\n\n\n\n\nPresentation #:\n\n\n\n\n1358O\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n\nA Transcriptomic Signature of AR Activity Prognosticates Development of Castration-Resistance following Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer\n\n\n\n\n\nPresenter:\n\n\n\n\nPhuoc Tran, MD, PhD, University of Maryland School of Medicine\n\n\n\n\n\nDate/Time:\n\n\n\n\nSeptember 11, 2022\n\n\n\n\n\nPoster #:\n\n\n\n\n1381P\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n\nTranscriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer\n\...